BMY

Bristol-Myers Squibb (BMY), a Health Care sector equity, has drawn disclosed trading activity from 16 members of Congress across 44 total transactions spanning from November 2020 through April 2026, with purchases and sales in exact balance at 22 apiece. Among the most active disclosers by trade count are Ro Khanna, Tommy Tuberville, Julie Johnson, and Daniel Goldman, and the record includes one bipartisan co-trading cluster in which members from different parties disclosed transactions in the same name. In the executive branch, 19 officials have separately disclosed 33 transactions in BMY, with the closest congressional and executive purchases falling one day apart in the public filing sequence — an overlap observed in independent disclosures across a multi-year window. Congressional interest in the name is moderate in breadth relative to large-cap health care names, and the even purchase-to-sale ratio reflects no directional skew in the aggregate disclosed record.